Merck KGaA looks to boost drug R&D alliances as the CFO crunches the numbers on development costs
Most everybody at the high end of the drug R&D business has more trial work on the table than they can afford to complete alone …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
